Dallas, Texas (PRWEB) March 06, 2013
This report, The World Market for Implantable and Needle-Free Drug Delivery details the types of drug delivery systems and technologies that are being used in 2012, as well as those that may become major market factors by the end of the forecast period. The report describes the industry, its relationship to various healthcare channels, and the trends for the future. The report's market analysis encompasses drug delivery technology and the revenues earned from licensing that technology. Secondly, it encompasses the pharmaceutical arena as well.
In this report, the market for Implantable and Needle-Free Drug Delivery Systems is segmented into two main categories:
- Needle-free drug delivery
- Implantable drug delivery including sustained release and targeted drug delivery
All segments of the drug delivery arena are experiencing rapid evolution. This is particularly evident within the implantable/injectable drug delivery sector. Meeting the challenges of drug delivery that are present today with biopharmaceuticals and emerging drugs requires innovation from drug delivery manufacturers. The expanding occurrence of emerging drugs combined with increased sensitivity to clinical outcomes and healthcare costs are driving the need for alternative drug delivery methods and devices. An aging population, high healthcare costs and healthcare reform initiatives are major forces driving growth.
As part of its extensive coverage, this report provides the following information:
- Select Products in Development by Drug Delivery Companies
- Implantable Drug Delivery Market Size and Forecast
- Needle-free Drug Delivery Market Size and Forecast
- Selected Needle-free/Auto-injector Systems and Manufacturers
- Drug Delivery Systems by Pharmaceutical and Drug Delivery Component
- Selected Suppliers of Implantable/Injectable Drug Delivery Technology
- Cost per Million Injections by Injector Type
- Seven Important Conclusions About the Market
- Profiles of Injectable/Implantable and Needle-Free Drug Delivery Companies
Large pharmaceutical companies have realized that they can substantially extend the period of exclusivity (and the competitive edge) of their products that are about to lose patent protection by delivering them in a novel way. This leads to a competitive edge after patent expiration or patent extension. Patent issues are a major driver of the industry. This leads to the development of collaborations and acquisitions between Big Pharma companies and drug delivery companies. Pharmaceutical manufacturers are seeking alternatives to conventional delivery systems to introduce patients to innovative platforms that promote compliance and reduce risks. This is putting pressure on the drug delivery companies to meet the demands and remain competitive in the implantable/injectable drug delivery. Within the implantable/injectable drug delivery market, there are a number of competitors. Competition in the segment has increased over the past 10 years, with top delivery technology companies such as ALZA, Pacira, Bioject, and Alkermes.
Needle-free jet injection devices can and should play a major role in solving the problems of needle-stick injuries and needle phobia in the United States. However, the needle-free jet injector industry is struggling to overcome significant obstacles in this country and abroad before these devices become widely accepted and used for administering drugs and especially vaccines. Most needle-free jet injectors use metal springs, compressed air, or CO2 gas to power the injection. The device's nozzle is held against the patient's skin and once activated; the device injects a fine stream of the vaccine or drug at a high pressure into the skin. The most common orifice size is 0.127 mm, whereas that of a 25-gauge needle is 1 mm.
As the discovery and development of new drugs create the promise of relief and improved levels of care for a variety of chronic conditions, developers are increasingly aware of the need to pair these promising new therapies, more than half of which cannot be taken orally, with delivery methods that are patient-friendly and that encourage compliance. For many drug developers, the answer to this challenge will increasingly be needle-free injection. While the concept behind needle-free injection is uncomplicated, it has only been recently, with the convergence of synthetic materials and computerized design software that reliable and cost-effective devices have begun to appear. New designs currently being developed will create new opportunities for needle-free injection.
The technology continues to advance as needle-free company marketers are evolving, searching for a strategy that will achieve commercial success. Companies have invested in new device models that incorporate design enhancements and improved engineering. The new generations of devices are lighter, have a sleek profile, and employ warm colors.
The number of companies providing implantable/injectable drug delivery platforms continues to proliferate. The implantable/injectable drug delivery industry is comprised of companies seeking to develop novel alternatives to existing delivery systems, enhancements to existing systems, commercially enabling delivery systems that provide viable alternatives for therapeutics that are not fully developed and marketed because there are limited practical means of administration.
This report provides profiles of the 15 major companies.
Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx?name=224710.
Explore more reports on Pharmaceutical Market.
ReportsnReports.com is an online market research reports library of 200,000+ in-depth studies of over 5000 micro markets.